MEK

<p>Lidocaine, an amide local anesthetic, reduces pain and inflammation by dampening ICAM-1, cytokines, and neutrophil influx.</p>

<p>Lidocaine Hydrochloride hydrate is an amide local anesthetic, has anti-inflammatory property.</p>

<p>Lidocaine HCl: local anesthetic, antiarrhythmic, stronger &amp; longer-lasting than procaine but shorter than bupivacaine/prilocaine.</p>

Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib which is a selective MEK inhibitor.

A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;

MEK1/2-IN-3 (Compound M15) is an inhibitor of MEK1, with an IC50 value of 10.29 nM. It effectively suppresses tumor cell proliferation and migration, induces apoptosis, and exhibits good liver microsomal stability. MEK1/2-IN-3 is applicable in the study of solid tumors.

MEK4 inhibitor-1 targets MEK4 enzyme in pancreatic cancer, IC50=61 nM.

PD 198306: a MEK inhibitor with antihyperalgesic properties, reduces Streptozocin-boosted active ERK1.

<p>MEK/PI3K-IN-1 (6r) is a dual MEK/PI3K inhibitor; IC50: 124 nM (MEK1), 130 nM (PI3Kα), 236 nM (PI3Kδ). It reduces pAKT, pERK1/2, and hinders tumor growth.</p>

<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>

Debromohymenialdisine is a natural product for research related to life sciences. The catalog number is T35596 and the CAS number is 75593-17-8.

BAY-6035 is an inhibitor of SET and MYND domain-containing protein 3 (SMYD3). BAY-6035 has more than 100-fold selectivity over other histone methyltransferases.

<p>MEK/PI3K-IN-2 is a potent dual inhibitor (MEK1 IC50: 352 nM, PI3Kα: 107 nM, PI3Kδ: 137 nM) that reduces pAKT, pERK1/2, and hinders tumor cell growth.</p>

Inactive analog of U0126(MEK-1/2 inhibitor), used as a negative control

NST-628 is a pan-RAF-MEK molecular glue that prevents RAF from phosphorylating and activating MEK. NST-628 inhibits the RAF-MEK signaling complex.

<p>DS03090629, an orally active MEK inhibitor, functions by competitively inhibiting MEK activity in the presence of ATP. This compound demonstrates strong binding affinity to both MEK and phosphorylated MEK, with dissociation constants (Kd) of 0.11 and 0.15 nM, respectively. It has shown efficacy in suppressing the proliferation of melanoma cell lines that overexpress BRAF mutations, achieving IC50 values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 is thus considered promising for anti-melanoma therapies.</p>

Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic acid-responsive gene during embryogenesis, but currently viewed as

Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic acid-responsive gene during embryogenesis, but currently viewed as

Anti-Midkine Antibody (5T766) is an antibody targeting Midkine. Anti-Midkine Antibody (5T766) can be used in ELISA, IHC.

Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic acid-responsive gene during embryogenesis, but currently viewed as